A10BH02 - Vildagliptin |
Propably not porphyrinogenic |
PNP |
Rationale
Vildagliptin is not a CYP substrate and has no capacity for inhibition or induction of the major CYP-subclasses. There are no pharmacokinetic drug interactions with vildagliptin as perpetrator.
Chemical description
Hydroxy admantan amino acetyl pyrrolidine carbonitrile
Therapeutic characteristics
Vildagliptin is indicated for the improvement of glycaemic control in adult patients with type 2 diabetes mellitus. It can be used as mono therapy or as part of combination therapy with other anti-diabetic drugs.
Vildagliptin increases the levels of endogenous incretin hormones via potent and selective inhibition of dipeptidyldipeptidase-4 (DPP-4). Nausea is a common side effect of vildagliptin that may potentially be porphyrinogenic through reduction in carbohydrate intake.
Metabolism and pharmacokinetics
Vildagliptin is not a CYP substrate; it is metabolized by hydrolysis mainly in the kidneys. It is devoid of capacities for induction or inhibition of any of the CYP-subclasses. There are no pharmacokinetic interactions with vildagliptin as perpetrator.
References
- Scientific articles
- Golightly LK, Drayna CC, et al. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012 Aug 1;51(8):501-14. #1126
- He YL. Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clin Pharmacokinet. 2012 Mar 1;51(3):147-62. PMID 22339447. #1127
- Scheen AJ. Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab. 2010 Aug; 12(8):648-58. PMID 20590741. #1114
- Summary of Product Characteristics
- The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Galvus. #1128
Similar drugs
© NAPOS 2024